Review Article
Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates
Translational Breast Cancer Research
2022;
3:
18
(30 April 2022)
Review Article
Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer
Translational Breast Cancer Research
2022;
3:
17
(30 April 2022)
Review Article
Narrative review of progress in pathological diagnosis of breast cancer
Translational Breast Cancer Research
2022;
3:
16
(30 April 2022)
Original Article
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study
Translational Breast Cancer Research
2022;
3:
15
(30 April 2022)
Original Article
The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients
Translational Breast Cancer Research
2022;
3:
14
(30 April 2022)
Guideline
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Translational Breast Cancer Research
2022;
3:
13
(30 April 2022)
Editorial
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update: adjuvant therapy for triple negative breast cancer in 2022
Translational Breast Cancer Research
2022;
3:
12
(30 April 2022)
Editorial
Escalating and de-escalating treatments in HR+HER2− early-stage breast cancer
Translational Breast Cancer Research
2022;
3:
11
(30 April 2022)
Editorial
CDK4/6 inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer
Translational Breast Cancer Research
2022;
3:
10
(30 April 2022)
Case Report
A fatal case of pneumonitis and hypogammaglobulinemia with use of a CDK4/6 inhibitor in metastatic breast cancer: case report
Translational Breast Cancer Research
2022;
3:
9
(31 January 2022)
Original Article
Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis
Translational Breast Cancer Research
2022;
3:
8
(31 January 2022)
Editorial Commentary
Monarch plus: a research review
Translational Breast Cancer Research
2022;
3:
7
(31 January 2022)
Editorial Commentary
Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer—comments on the Monarch plus study
Translational Breast Cancer Research
2022;
3:
6
(31 January 2022)
Editorial Commentary
MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunities
Translational Breast Cancer Research
2022;
3:
5
(31 January 2022)
Review Article
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
Translational Breast Cancer Research
2022;
3:
4
(31 January 2022)
Review Article
Role of abemaciclib in primary breast cancer: a narrative review of MonarchE
Translational Breast Cancer Research
2022;
3:
3
(31 January 2022)
Review Article
Innovation drug approvals based on a bridging study: from concept to practice
Translational Breast Cancer Research
2022;
3:
2
(31 January 2022)
Meet the Professor
The legend of MONARCH: Chinese breast cancer experts from participation in to leading global clinical study and boosting treatment area development
Translational Breast Cancer Research
2022;
3:
1
(31 January 2022)
Consensus
Chinese expert consensus on coronavirus disease 2019 vaccination for breast cancer patients
Translational Breast Cancer Research
2021;
2:
34
(31 October 2021)
Case Report
Case report: rare breast tumor—Schwannoma of the breast
Translational Breast Cancer Research
2021;
2:
33
(31 October 2021)
Case Report
More than 14 years’ progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report
Translational Breast Cancer Research
2021;
2:
32
(31 October 2021)
Editorial Commentary
DESTINY-Breast01 Trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer
Translational Breast Cancer Research
2021;
2:
31
(31 October 2021)
Review Article
Current understandings and prospects of antibody-drug conjugates (ADCs) for the treatment of breast cancer: a narrative review
Translational Breast Cancer Research
2021;
2:
30
(31 October 2021)
Review Article
A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer
Translational Breast Cancer Research
2021;
2:
29
(31 October 2021)
Review Article
Sacituzumab govitecan in breast cancer
Translational Breast Cancer Research
2021;
2:
28
(31 October 2021)